Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lumasiran - Alnylam Pharmaceuticals

Drug Profile

Lumasiran - Alnylam Pharmaceuticals

Alternative Names: ALN-GO1; Lumasiran

Latest Information Update: 14 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action Glycolate oxidase expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary hyperoxaluria
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Primary hyperoxaluria

Most Recent Events

  • 12 Jan 2020 Alnylam Pharmaceuticals intends to market lumasiran in year 2020
  • 10 Jan 2020 Preregistration for Primary hyperoxaluria (In adolescents, In children, In adults) in USA (SC)
  • 10 Jan 2020 Alnylam expects approval for Primary hyperoxaluria from the US FDA in late 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top